ArticleFrontiers in pharmacology2021

SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy.

Elena De Mattia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.